Effect of Dexmedetomidine on Hemodynamic Response to Endotracheal Intubation in Hypertensive Patients

Summary

Dexmedetomidine, an alpha-2 adrenergic agonist, has been shown to provide several benefits during endotracheal intubation: 1. \_Reduced anxiety and stress\_: Dexmedetomidine's anxiolytic and sedative effects help reduce anxiety and stress associated with endotracheal intubation. 2. \_Improved intubating conditions\_: Dexmedetomidine can improve intubating conditions by reducing the incidence of coughing, bucking, and laryngospasm. 3. \_Decreased hemodynamic responses\_: Dexmedetomidine can attenuate the hemodynamic responses to intubation, including tachycardia, hypertension, and increased cardiac output. 4. \_Increased ease of intubation\_: Dexmedetomidine can facilitate smoother and easier intubation by reducing the need for additional anesthetics or muscle relaxants. The physiological responses to dexmedetomidine during intubation include: 1. \_Decreased heart rate\_: Dexmedetomidine can cause a decrease in heart rate due to its effects on the sympathetic nervous system. 2. \_Decreased blood pressure\_: Dexmedetomidine can also cause a decrease in blood pressure due to its vasodilatory effects. 3. \_Increased sedation\_: Dexmedetomidine's sedative effects can help reduce anxiety and stress during intubation. 4. \_Reduced respiratory rate\_: Dexmedetomidine can cause a decrease in respiratory rate due to its effects on the respiratory centers in the brain. The clinical benefits of dexmedetomidine during intubation include: 1. \_Improved patient comfort\_: Dexmedetomidine's sedative and anxiolytic effects can improve patient comfort during intubation. 2. \_Reduced need for additional anesthetics\_: Dexmedetomidine can reduce the need for additional anesthetics or muscle relaxants during intubation. 3. \_Decreased risk of complications\_: Dexmedetomidine's effects on hemodynamic responses and respiratory rate can decrease the risk of complications during intubation.

Timeline

Start

2024-06-22

Primary completion

2024-11-22

Completion

2024-12-01

Drugs

Indications